Amarin Announces $100 Million Non-Equity Financing and Vascepa Sales Force Hiring While Continuing to Assess Strategic

Amarin Announces $100 Million Non-Equity Financing and Vascepa Sales Force
Hiring While Continuing to Assess Strategic Alternatives

Steps Are Consistent With Amarin's Continuation of Its Strategy to Parallel
Process Three Strategic Options

Conference Call Scheduled for Today, December 6th at4:30 p.m. ET

BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 6, 2012 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, announced today a $100 million non-equity financing with an investment
fund managed by Pharmakon Advisors and that Amarin is continuing its
preparations to commercialize Vascepa^® (icosapent ethyl) capsules with the
hiring of a sales force in the United States. Payments by Amarin under this
hybrid debt-like instrument are expected to be made over a 3.5-year period
commencing in November 2013 and to continue through early 2017.

As previously announced, the initial commercial launch of Vascepa is planned
for early in the first quarter of 2013. The company is hiring 250-300
specialty sales professionals for the launch of Vascepa for its initial
indication, the MARINE indication, which is approved by the U.S. Food and Drug
Administration (FDA). Amarin's goal is for every sales representative hired to
have, at a minimum, three to five year existing relationships with the
identical physician groups Amarin will be calling on and educating about
Vascepa.

In addition to hiring a sales force, Amarin has been focused on continued
commercial preparations for Vascepa which, as previously disclosed, has
included, but has not been limited to, finalizing the introduction of Vascepa
to managed care plans to gain formulary access, building up inventory levels,
hiring key personnel (e.g., managed care, marketing, sales infrastructure,
pricing), developing direct-to-consumer advertising and speaker training and
coordinating other pre-launch marketing activities.

Amarin's hiring of a sales force is part of a continuing strategy to evaluate
three potential paths to Vascepa commercialization: an acquisition ofAmarin,
a strategic collaboration, and self-commercialization, the latter of which
could include third-party support.

"This transaction provides Amarin with non-dilutive capital that will ensure
our ability to fully execute on the Vascepa product launch while continuing
our strategic partnership discussions," stated Joseph Zakrzewski, Chairman and
CEO of Amarin. "This innovative transaction allows maximum flexibility for
Amarin."

Vascepa's next indication, for the patient population studied in the ANCHOR
Phase 3 trial, remains on target for a Supplemental New Drug Application
(sNDA) submission to the FDA by the end of February 2013 resulting in an
anticipated PDUFA action date for the ANCHOR sNDA before the end of 2013.

Conference call for investors

Amarin will host a conference call and webcast for investors, today at 4:30
p.m. ET to discuss the above topics. The conference call will be webcast live
and a link to the webcast may be accessed from the "Events & Presentations"
page on the Amarin corporate website at www.amarincorp.com.

To listen to the live call on the telephone, dial 1-877-407-8033 (United
States and Canada) or 1-201-689-8033 (International). The conference call ID
number is 405508. A replay of the call will be available for 30 days by
dialing 1-877-660-6853 (United States and Canada) or 1-201-612-7415
(International), conference ID 405508.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit
www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

The Amarin Corporation plc logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13817

About Pharmakon Advisors

Funds managed by Pharmakon Advisors, including BioPharma-II, invest in debt
securities and capped royalties secured by revenues from life sciences
products. Pharmakon Advisors' management team has a long and successful track
record of structuring securitized financings and making direct investments in
royalty interests on life sciences products. Pharmakon manages approximately
$625 million and has structured investments secured by royalty payments on
fifteen different pharma, biotech and medical device products.

Forward-looking statements

This press release contains forward-looking statements, including statements
about the timing of a commercial launch of Vascepa, preparations for
commercial launch, the potential for an acquisition of Amarin or a strategic
collaboration with a third party for the commercialization of Vascepa,
assurances regarding the amount of Amarin's revenues from Vascepa and the
timing of future payments owed to the Pharmakon-managed investment fund under
the financing agreement, and Amarin's current expectations regarding the
submission of a Supplemental New Drug Application (sNDA) to the FDA by the end
of February 2013 for the ANCHOR indication for Vascepa. These forward-looking
statements are not promises or guarantees and involve substantial risks and
uncertainties. Among the factors that could cause actual results to differ
materially from those described or projected herein include the following:
risks associated with the planned commercial launch of Vascepa and
preparations related thereto, including the timing of the hiring of the
specialty sales force, acceptance by physicians and patients of Vascepa, and
reimbursement decisions of government or private insurances; the timing of
future regulatory submissions, FDA's response to any of the company's current
and future submissions, including FDA's determination of the regulatory
exclusivity status for Vascepa and the timing and determination of Amarin's
planned sNDA for the ANCHOR indication; Amarin's ability generally to maintain
adequate patent protection and successfully enforce patent claims against
third parties; commercializing Vascepa without violating the intellectual
property rights of others; and uncertainties associated generally with
research and development, clinical trials and related regulatory approvals and
commercialization. A further list and description of these risks,
uncertainties and other risks associated with an investment in Amarin can be
found in Amarin's filings with the U.S. Securities and Exchange Commission,
including its most recent Quarterly Report on Form 10-Q. Existing and
prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. Amarin
undertakes no obligation to update or revise the information contained in this
press release, whether as a result of new information, future events or
circumstances or otherwise.

CONTACT: Amarin contact information:
         Stephen D. Schultz
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.